167 related articles for article (PubMed ID: 8221559)
1. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP).
Ardizzoni A; Rosso R; Salvati F; Scagliotti G; Soresi E; Ferrara G; Pennucci C; Baldini E; Cruciani AR; Antilli A
Am J Clin Oncol; 1991 Apr; 14(2):120-3. PubMed ID: 1851386
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial.
Zarogoulidis K; Ziogas E; Papagiannis A; Charitopoulos K; Dimitriadis K; Economides D; Maglaveras N; Vamvalis C
Lung Cancer; 1996 Sep; 15(2):197-205. PubMed ID: 8882986
[TBL] [Abstract][Full Text] [Related]
6. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
Halme M; Maasilta PK; Pyrhönen SO; Mattson KV
Eur J Cancer; 1994; 30A(1):11-5. PubMed ID: 8142151
[TBL] [Abstract][Full Text] [Related]
7. Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
Cellerino R; Tummarello D; Porfiri E; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1839-43. PubMed ID: 2851443
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.
Schiller JH; Storer B; Dreicer R; Rosenquist D; Frontiera M; Carbone PP
J Natl Cancer Inst; 1989 Nov; 81(22):1739-43. PubMed ID: 2553993
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
[TBL] [Abstract][Full Text] [Related]
11. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
Kelly K; Crowley JJ; Bunn PA; Hazuka MB; Beasley K; Upchurch C; Weiss GR; Hicks WJ; Gandara DR; Rivkin S
J Clin Oncol; 1995 Dec; 13(12):2924-30. PubMed ID: 8523056
[TBL] [Abstract][Full Text] [Related]
12. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force.
Rosso R; Salvati F; Ardizzoni A; Gallo Curcio C; Rubagotti A; Belli M; Castagneto B; Fusco V; Sassi M; Ferrara G
Cancer; 1990 Jul; 66(1):130-4. PubMed ID: 2162239
[TBL] [Abstract][Full Text] [Related]
13. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.
Vokes EE; Haraf DJ; Hoffman PC
Cancer Chemother Pharmacol; 1993; 33(3):203-9. PubMed ID: 8269601
[TBL] [Abstract][Full Text] [Related]
14. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V; Yap A
Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
[TBL] [Abstract][Full Text] [Related]
15. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
16. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.
Prior C; Oroszy S; Oberaigner W; Schenk E; Kummer F; Aigner K; Hausmaninger H; Peschel C; Huber H
Eur Respir J; 1997 Feb; 10(2):392-6. PubMed ID: 9042638
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
